STAT+: A Novartis drug cut inflammation. Can it improve heart outcomes?
Source ↗
👁 0
💬 0
A newly acquired Novartis drug successfully lowered signs of inflammation in a midstage study, as experts wait to hear how the company plans to advance the drug as a potential cardiovascular treatment. 
In the Phase 2 TRANQUILITY study, the drug, pacibekitug, led to sustained decreases in biomarkers of inflammation, according to results presented Saturday at the European Society of Cardiology’s annual meeting in Munich. Investigators reported a dose-dependent drop in biomarker lev
In the Phase 2 TRANQUILITY study, the drug, pacibekitug, led to sustained decreases in biomarkers of inflammation, according to results presented Saturday at the European Society of Cardiology’s annual meeting in Munich. Investigators reported a dose-dependent drop in biomarker lev
Comments (0)